Articles

Positive correlation between psoriasis vulgaris severity degree with HbA1C level

Made Swastika Adiguna , Made Wardhana, Fresa Nathania Rahardjo

Made Swastika Adiguna
Dermatology and Venereology Departement, Faculty of Medicine, Udayana University, Sanglah General Hospital Denpasar, Bali-Indonesia. Email: adiguna_bali@yahoo.co.id

Made Wardhana
Dermatology and Venereology Departement, Faculty of Medicine, Udayana University, Sanglah General Hospital Denpasar, Bali-Indonesia

Fresa Nathania Rahardjo
Post Graduate in Dermatology and Venereology Departement, Faculty of Medicine, Udayana University, Sanglah General Hospital Denpasar, Bali-Indonesia
Online First: July 14, 2019 | Cite this Article
Adiguna, M., Wardhana, M., Rahardjo, F. 2019. Positive correlation between psoriasis vulgaris severity degree with HbA1C level. Bali Dermatology and Venereology Journal 1(2). DOI:10.15562/bdv.v1i2.11


Introduction: Psoriasis is a skin abnormality based on chronic inflammation immune mediated. Inflammatory mediator roles (Th-1, TNF-α, IL-6,IL-7, IL-8, IL-17, and IL-23) in its pathogenesis proven to inhibit insulin receptor and glucose uptake from fat tissue and causing insulin resistance, then blood glucose level increased. Mean blood glucose level within 3 months can be represented by HbA1c (glycosylated haemoglobin) level. HbA1c is a bond between glucose and hemoglobin.           

Objective: The aim of this study is to understanding correlation between psoriasis vulgaris severity degree with HbA1c.

Material and methods: This study is using cross sectional method. HbA1c level examination done by drawing venous blood, then analyzed with chromatography method. Samples were selected by using inclusion and exclusion criteria and consecutive sampling method.

Result: Study result shows subject consist of total 51 subjects consists of 33 subjects with psoriasis vulgaris (22 males and 11 females with youngest age of 15 and oldest age of 65 years old), and 18 subjects without psoriasis vulgaris. Psoriasis vulgaris severity degree measured with Psoriasis Area Severity Index (PASI), then grouped to 3 categories: mild PASI score <6, moderate PASI score  6 – 12, and severe PASI score> 12. Mostly  (15 subjects) including mild category. HbA1c level on this study subjects resulted minimum level of 4.6%, maximum 12.1 %, and median 5.4%.  Based on Perkeni consensus, normal HbA1c level is <5,7%, prediabetes 5,7-6,4%, and diabetes >6,5%. HbA1c level of psoriasis vulgaris subjects are higher than non psoriasis vulgaris subjects significantly (p=0,019). Psoriasis vulgaris causing increase of HbA1c level with Prevalence Ratio (PR) 6,55. Thus, Psoriasis vulgaris subjects have increased risk 6,5 times to increase HbA1c level compared with non psoriasis vulgaris subjects. Correlation between severity degree and HbA1c level found in positive course significantly with moderate strength of correlation (Spearman correlation; r = 0.580, p<0,001).

Conclusion: HbA1c level on psoriasis vulgaris subjects are higher than non psoriasis vulgaris, and psoriasis vulgaris severity degree positively correlated with HbA1c increasing level. Every increase of  psoriasis vulgaris severity degree will cause increase level of  HbA1c.

References

Meher C., Iswara LK., Roesyanto-Mahadi ID. The role of single nucleotide Interleukin-6 (IL-6) polymorpishm gene in psoriasis vulgaris patients at Haji Adam Malik Central Hospital, Medan-Indonesia. Bali Med J. 2018;7(1):79-81

Gudjonsson JE, Elder JT. 2012. Psoriasis. Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York: McGraw-Hill; 2012. p.197-231.

Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. 2014. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol.; 71: 141-50.

Chen L, Chen R, Wang H, Liang F.,2015. Mechanisms Linking Inflammation to Insulin Resistance.Int J of Endocrinol vol 1(1):1-9.

Goreschi K., Weigert C. and Rocken M., 2010. Immunopathogenesis and Role of T cell in psoriasis. Clin in Dermatol; 25: 574-580.

Brezinski E.A., Follansbee M.R., Amstrong E.J and Armstrong A.W., 2013. Endothelial Dysfunction and the Effect of TNF Inhibitors on the Endothelium in Psoriasis and Psoriatic Arthritis: A Systemic Review. Curr Pharm: 2: 8-12.

Flatz L, Conrad C., 2013. Role of t-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy. Dove Press J vol 3:1-10.

Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A, Sanusi H, Lindarto D, Shahab A, Pramono B, Langi YA,Purnamasari D, Soetedjo NN, Saraswati MR, Dwipayana MP, Yuwono A, Sasiarini L, Sugiarto,. Sucipto KW, Zufry H., 2015. Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia. Konsensus Perkeni.

Ashcroft DM., Li WP., 2008. Therapeutic Strategies for Psoriasis. J of Clin Pharm and Ther; 25: 1-10.

Charakida, A., Dadzie, O., Teixeria, F., Evangelou, G., Chu, A.C. 2006. Calcipotriol/bethametasone dipropionate for the Treament of Psoriasis. Expert Opin. Pharmacother.; 7(5): 597-606.

Dahri G.M, Samdani, A.J., Qasi, N., Laghari, M.J., Wagan, M.A. 2010. To compare the Role of Calcipotriol Alone Versus Combination with Betamethasone in Milpid to Moderate Psoriasis. Sindh Univ. Res. Jour. (Sci. Ser.); 42(1): 69-72.

Rajabi S, Mazloom Z, Zamani A, Tabatabaee HR. Effect of low glycemic index diet versus metformin on metabolic syndrome. 2015. Int J Endocrinol Metab; 13(4): 1-5.

Setyorini M, Triestianawati W, Wiryadi BE, Alam Jacoeb TN. Proporsi Sindrom Metabolik pada Penderita Psoriasi Vulgaris Berdasarkan Kriteria National Cholesterol Education Program Adult Treatment Panel III di RS DR. Cipto Mangunkusumo dan Sebuah Klinik Swasta di Jakarta. MDVI. 2012;39(1):2-9

Huerta C, Rivero E, Rodriguez LA. Incidence and risk factor for psoriasis in the general population. Arch Dermatol. 2007;143(12):1559-65.

Takahashi H, Takahashi I, Honma M, Ishida-Yamamoto A, Iizuka H. Prevalence of metabolic syndrome in Japanese psoriasis patients. J Dermatol Sci. 2010;57(2):143-4

Aruna C, Rao GV, Ramanamurthy P, Rambabu P. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case control study from a tertiary care center in Andhra Pradesh. J NTR Univ Health Sci. 2016;5:13-6

Milcic D, Jankovic S. Vesic S. Milinkovic M. Marinkovic J. Circovic A. Jankovic J. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross sectional study. An Bras Dermatol. 2017;92(1):46-51

Gisondi P. Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157(1):68-73

Salunke AS, Nagargoje MV, Belgaumkar VA, Tolat SN, Chavan RB. Association of Metabolic Syndrome in Chronic Plaque Psoriasis Patients and their Correlation with Disease Severity, Duration and Age: A Case Control Study from Western Maharashtra. J. Clin Diagn Res. 2017;11(8):WC06-WC10

Davidovici B.B, Sattar, N., Jo, P.C., Puig, L., Emery, P., Barker, J.N., Kerkhof, P., Stahle, M., 8, Nestle, F., Girolomoni, G. dan Krueger, J.G. 2010. Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions. J of Invest Dermatol, 130: 1785–1796.

Elegendy A, Alshawadfy E, Altaweel A, Elsaidi A. Cardiovascular and Metabolic Comorbidities of Psoriasis. Psoriasis and Rosacea. 2016;1(1):1-9

Sing S, Taylor C, Kornmehl H, Armstrong AW. Psoriasis and suicidality: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2017;77(3):425-440.e2


Article Views      : 54
PDF Downloads : 26